Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Priapism × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 55 Breast Neoplasms 32 Neoplasms 30 Multiple Myeloma 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Recurrence 19 Leukemia, Myeloid, Acute 18 Colorectal Neoplasms 16 Lymphoma, Non-Hodgkin 15 Neoplasm Metastasis 15 Leukemia 14 Leukemia, Lymphocytic, Chronic, B-Cell 14 Melanoma 14 Carcinoma, Renal Cell 13 Lymphoma, Follicular 12 Ovarian Neoplasms 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Lung Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 10 Myelodysplastic Syndromes 10 Adenocarcinoma 9 Carcinoma, Hepatocellular 9 Hematologic Neoplasms 9 Urinary Bladder Neoplasms 9 Carcinoma 8 Head and Neck Neoplasms 8 Lymphoma, B-Cell, Marginal Zone 8 Lymphoma, Mantle-Cell 8 Prostatic Neoplasms 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed

198 enrolled 18 charts 1 FDA

Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡